Hapeville is a compact city, a Main Street district built around the 1890 depot with neighborhoods like Virginia Park, Old 1st Ward and Happy Homes close in around it. That closeness cuts both ways. Neighbors know each other, which is good for accountability and hard for privacy, and more than one patient has told us they preferred driving up to Buckhead precisely because it was away from the block. Whatever brings you in, the evaluation is the same: history, medications, labs where indicated, and a conversation about what has and has not worked for you before.
Treatment may involve medication, including GLP-1 medications, and it may involve addressing conditions that sit alongside obesity, such as thyroid issues or hormone changes. Which of those apply is determined by your physician after the workup, not by a package chosen in advance. Our doctors, Dr. Elbridge Bills, Dr. Jeff Semel and Dr. Leslye Pace, have been practicing this way since the clinic opened in 2010, and the emphasis is on sustained management rather than a short burst of weight loss followed by whatever comes next.
Getting to us from Hapeville is straightforward even if it is not short. Virginia Avenue or North Central Avenue to I-75/I-85, the Connector north, GA-400 north, then west toward Roswell Road NE for Chastain Park and Buckhead. I-285 around the west side to the Roswell Road exit works for drivers avoiding downtown. Call (404) 341-4819 and we will find a time that fits around your work.
About Obesity Treatment
Obesity is a chronic medical condition, not a character flaw or a willpower problem. Excess adipose tissue changes how the body regulates hunger, satiety, insulin, blood pressure, inflammation, and energy expenditure, and those changes persist long after a diet ends. That is why most people who lose weight through effort alone regain it: the body actively defends its previous weight. Treating obesity as the metabolic disease it is means using medical tools, ongoing physician oversight, and a plan built for years rather than weeks.
Medicine has moved quickly here. A 2025 international commission proposed diagnosing obesity by organ and tissue function rather than by body mass index alone, separating people who carry excess weight without current illness from those whose health is already affected. In 2026 the American College of Physicians placed the GLP-1 medications semaglutide and tirzepatide as first-line drug therapy for adults with a BMI of 30 or higher, and for adults with a BMI of 27 or higher who also have a condition such as type 2 diabetes, high blood pressure, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Guidance now also discourages requiring patients to fail repeated diet attempts before medication is considered.
Atlanta Medical Institute has treated obesity as a physician-directed medical condition since 2010. Care is directed by Dr. Elbridge Bills, Dr. Jeff Semel, and Dr. Leslye Pace from the practice's single office on Roswell Road in Atlanta, and patients travel in from across the metro area. Treatment starts with an evaluation, not a prescription: your physician looks at your history, your weight-related conditions, your medications, and relevant laboratory work before deciding whether medication is appropriate for you and, if so, which one. No clinic can promise a specific amount of weight loss, and any program that does is selling rather than treating.
What medical obesity treatment involves
Obesity treatment at AMI begins with a physician visit that establishes what is actually driving weight gain and what it has already affected. Weight and body measurements are part of that picture, but so are blood pressure, metabolic and thyroid labs where indicated, sleep symptoms, joint pain, prior weight history, and the full list of medications you take, since several common drugs promote weight gain and sometimes can be substituted.
From there your physician builds a plan. For many patients that includes an FDA-approved anti-obesity medication alongside nutrition and activity changes. The approved options include the GLP-1 and dual-agonist injectables semaglutide and tirzepatide, an oral 25 mg semaglutide tablet approved in late 2025, liraglutide, and older oral agents such as phentermine, phentermine with topiramate, naltrexone with bupropion, and orlistat. Some of these suit a patient with reflux or migraine or hypertension better than others, which is the point of a physician choosing rather than a website.
Medication is a tool inside a program, not the whole program. Protein intake, resistance training to protect lean tissue, sleep, and management of the conditions that travel with obesity all affect how well treatment works and how durable the result is.
- Physician evaluation of weight history, weight-related conditions, and current medications
- Laboratory work as clinically indicated, including metabolic and thyroid studies
- Discussion of every appropriate FDA-approved medication option, not one product
- A nutrition and activity plan built around protecting muscle while losing fat
- Scheduled follow-up visits to adjust dosing and monitor response
- Coordination with your primary care physician or specialists when your care overlaps
Who is a candidate
Current guidance supports pharmacologic treatment for adults with a BMI of 30 or greater, and for adults with a BMI of 27 or greater who also carry at least one weight-related condition such as type 2 diabetes, prediabetes, high blood pressure, high cholesterol, fatty liver disease, obstructive sleep apnea, or established cardiovascular disease. BMI is a starting point rather than a verdict, and your physician will weigh waist measurement, body composition, and actual organ effects alongside it.
Candidacy is a medical decision made at your visit. Some patients are not appropriate for GLP-1 therapy: the labels for semaglutide and tirzepatide carry a boxed warning against use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and these medications are not used in pregnancy or while trying to conceive. A history of pancreatitis, significant gastroparesis, active gallbladder disease, severe kidney impairment, or certain eating disorders calls for careful review and sometimes a different approach entirely.
Patients who are not candidates for one medication are often candidates for another. That is one reason the evaluation matters more than the drug name people arrive asking for.
- BMI of 30 or higher, or 27 or higher with a weight-related medical condition
- Weight that is affecting blood pressure, blood sugar, lipids, sleep, joints, or liver
- Prior weight loss that did not hold, which is the expected pattern rather than a failure
- Willingness to attend follow-up visits, since dosing is adjusted over time
- No contraindication identified during your medical evaluation
What to expect over the first year
Injectable and oral GLP-1 medications are started at a low dose and increased gradually. The slow escalation is deliberate: it gives the digestive system time to adapt and reduces nausea, and it also means meaningful change is measured over months rather than the first few weeks. Your physician determines the pace, and it is normal for one patient to hold at a dose while another moves up.
Results vary widely from person to person, and published trial averages are not a forecast for any individual. What your physician tracks is broader than the scale: blood pressure, blood sugar and A1c, lipids, waist measurement, energy, joint symptoms, sleep quality, and how well you are eating. Several obesity medications now carry indications for specific related conditions, including tirzepatide for moderate to severe obstructive sleep apnea in adults with obesity and semaglutide for cardiovascular risk reduction in adults with established cardiovascular disease and for certain stages of metabolic dysfunction-associated steatohepatitis.
Obesity behaves like other chronic conditions in one important way. A 2026 systematic review found that, on average, people regained roughly 60 percent of the weight lost on GLP-1 therapy within a year of stopping it. That is not a reason to avoid treatment; it is a reason to plan the long-term phase with your physician rather than assume a course of medication is a one-time event.
Safety, monitoring, and honest limits
The common side effects of GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, reflux. Most are dose-related and ease with time or a slower titration. Less common but more serious concerns include pancreatitis, gallbladder problems, kidney injury from dehydration during prolonged vomiting, and increased heart rate. Anyone on these medications who is scheduled for surgery or a procedure under sedation should tell the anesthesia team, because delayed stomach emptying affects preoperative planning.
Rapid weight loss also costs lean tissue. A meaningful share of the weight lost on any effective obesity treatment can come from muscle rather than fat, which is why adequate protein and resistance training are part of the plan rather than optional extras. Your physician monitors this alongside your labs at follow-up visits.
One point AMI states plainly: compounded semaglutide and tirzepatide are not FDA-approved products. The FDA removed both drugs from its shortage list in 2024 and 2025, and in April 2026 proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances large outsourcing facilities may compound. Compounded versions, including salt forms sold online, have not been evaluated by the FDA for safety or effectiveness. Discuss with your physician what you are being prescribed and why.
- Scheduled follow-up visits while dosing is adjusted, then at intervals your physician sets
- Laboratory monitoring as clinically indicated for your history and medications
- Prompt reporting of severe abdominal pain, persistent vomiting, or signs of dehydration
- Telling any surgeon or anesthesiologist that you are taking a GLP-1 medication
- Attention to protein intake and resistance training to protect lean mass
- A clear conversation about what is FDA-approved and what is not
Getting Here from Hapeville
Patients from Hapeville generally pick up Virginia Avenue or North Central Avenue to reach I-75/I-85, ride the Downtown Connector north, then take GA-400 north and cut west toward Roswell Road NE for the Buckhead and Chastain Park area; drivers who prefer to stay off the Connector use I-285 around the west side to the Roswell Road exit.
5009 Roswell Road NE, Suite 201
Atlanta, GA 30342
We see patients from across Hapeville and nearby areas including Virginia Park, Old 1st Ward, Glenrose Heights, Moreland Park, Hammond Park.
Obesity Treatment in Hapeville — Frequently Asked Questions
Is this a diet program?
No. It is medical treatment for a chronic condition, delivered by physicians. Nutrition is part of it, but so are labs, medication review and management of related health conditions.
Do I need a referral?
No referral is required. Call (404) 341-4819 to schedule an evaluation at our office at 5009 Roswell Road NE, Suite 201, Atlanta, GA 30342.
Can obesity treatment help with conditions I already have?
Obesity frequently occurs alongside other conditions, and your physician will review those as part of the evaluation. Any effect on them is individual, and you should keep your other treating physicians in the loop.
Is obesity really a disease, or just a weight problem?
Major medical bodies treat obesity as a chronic disease. Excess adipose tissue alters hormonal signaling, appetite regulation, insulin sensitivity, blood pressure, and inflammation, and those changes persist and push weight back up after dieting. A 2025 international commission went further and proposed diagnosing obesity by its effect on organ and tissue function rather than by BMI alone. Treating it medically reflects that biology.
Do I have to fail at dieting before AMI will consider medication?
No. Current guidance, including the American College of Physicians' 2026 recommendation, does not require patients to try and fail lifestyle changes before starting pharmacotherapy. Your physician makes the decision based on your BMI, your weight-related conditions, your medical history, and your goals. Nutrition and activity remain part of the plan either way, but they are not a hurdle you must clear first.
How do you decide which medication is right for me?
Your physician considers your BMI, the weight-related conditions you already have, your other medications, your history with prior treatments, your tolerance for injections versus pills, and any contraindications. Semaglutide and tirzepatide are first-line for many adults, but they are not right for everyone, and older oral medications are a better fit for some patients. Eligibility for any of them is determined by medical evaluation, not by an online questionnaire.
What happens if I stop the medication?
Weight regain is common after stopping. A 2026 systematic review found that people regained about 60 percent of the weight they had lost within a year of discontinuing GLP-1 therapy, with regain tending to plateau after that. Obesity is a chronic condition, so your physician will talk with you about maintenance dosing, tapering, or other long-term strategies rather than treating a course of medication as a finish line.
Are compounded GLP-1 medications the same as Wegovy or Zepbound?
No. Compounded semaglutide and tirzepatide are not FDA-approved, and the agency has warned about unapproved salt forms sold online. The FDA removed both medications from its shortage list in 2024 and 2025 and in April 2026 proposed permanently excluding them from the bulk substances outsourcing facilities may use. Ask any provider directly whether what they are prescribing is an FDA-approved product.
Will treating obesity help the other conditions I have?
It often helps, though no one can promise a particular result for an individual. Sustained weight reduction is associated with improvement in blood pressure, blood sugar, lipids, sleep apnea severity, and joint symptoms for many patients. Some medications now carry specific indications: tirzepatide for moderate to severe obstructive sleep apnea in adults with obesity, and semaglutide for cardiovascular risk reduction in adults with established cardiovascular disease and for certain stages of fatty liver disease with fibrosis. Your physician will tell you what is realistic in your case.
Want the full clinical detail? Read about our Obesity Treatment program.